A high-accuracy, low-cost blood test for Alzheimer’s disease: validating P-tau181/Aβ42 in real-world cohorts
Flow cytometry-based P-tau181/Aβ42 offers a cost-effective and accurate diagnostic method for AD, with performance comparable to SIMOA. This biomarker supports scalable AD screening in secondary healthcare settings, overcoming accessibility and cost barriers in resource-limited environments. This biomarker supports scalable AD screening in secondary healthcare settings, overcoming accessibility and cost barriers in resource-limited environments.
Authors
- Yulan Chu
- Yuanyuan Tang (ORCID: https://orcid.org/0000-0001-6873-9467)
- Xiaodong Jia (ORCID: https://orcid.org/0000-0002-2145-6272)
- Haiyan Li (ORCID: https://orcid.org/0000-0002-1437-4383)
- Hailan Zhou
- Wenying Yu (ORCID: https://orcid.org/0000-0003-1567-1723)
- Qing Liu (ORCID: https://orcid.org/0000-0003-2028-973X)
- Tong Li (ORCID: https://orcid.org/0000-0002-4283-0091)
- Hang Li (ORCID: https://orcid.org/0000-0002-1875-2951)
- Keqiang Yan (ORCID: https://orcid.org/0000-0002-5124-9901)
- Dequan Liu (ORCID: https://orcid.org/0009-0003-1242-8792)
- Kaiting Cheng
Institutions
- Kingmed Diagnostics (CN)
Publication Details
- Journal
- Frontiers in Aging Neuroscience
- Published
- 2025-06-16
- DOI
- https://doi.org/10.3389/fnagi.2025.1599761
- Citations
- 1
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Guangzhou Municipal Science and Technology Project